Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Coast To Coast Tribune.
Press releases published on June 16, 2025
Plato Gold Announces Closing of Loan Financing for First Ever Drill Program at Lolita Project, Santa Cruz, Argentina
GlobeNewswire
·
June 16, 2025
Toronto, June 16, 2025 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (FRANKFURT: 4Y7 OR WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of properties in Northern Ontario and Santa Cruz, Argentina announces …
Discovery Announces Management Appointments
GlobeNewswire
·
June 16, 2025
TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced the hiring of Amy Hu as Senior Vice President, Legal and Sustainability and Darin Smith as Senior Vice President, …
Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology
GlobeNewswire
·
June 16, 2025
Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s research on influenza vaccines self-administered via …
RYVYL Executes Strategic Actions Enhancing Its Business Plan and Files S-1 Registration Statement
GlobeNewswire
·
June 16, 2025
- Unveils Plans to Initiate Digital Asset Acquisition Strategy – - Enters LOI to Acquire Complementary Entity – - Realigns Corporate and North America Operations - SAN DIEGO, CA, June 16, 2025 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the " …
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
GlobeNewswire
·
June 16, 2025
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025 Initial Phase 1 …
RYVYL Appoints Industry Veteran Brett Moyer to Its Board of Directors
GlobeNewswire
·
June 16, 2025
SAN DIEGO, CA, June 16, 2025 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company"), a leading innovator of payment transaction solutions leveraging electronic payment technology, has appointed industry veteran Brett Moyer as an …
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewswire
·
June 16, 2025
MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared …
Mark Ford Joins Highway as Chief Capacity Officer
GlobeNewswire
·
June 16, 2025
DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Highway announced today that Mark Ford will join the company as Chief Capacity Officer, a strategic addition to the executive team as the company accelerates growth and advances its long-term vision to redefine …
OTC Markets Group Welcomes Southpoint Bancshares Inc. to OTCQX
GlobeNewswire
·
June 16, 2025
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Southpoint Bancshares Inc. (OTCQX: SOUB), which operates primarily in the …
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
GlobeNewswire
·
June 16, 2025
– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity – JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE …
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
GlobeNewswire
·
June 16, 2025
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( …
Flagship Communities Real Estate Investment Trust Announces June 2025 Cash Distribution
GlobeNewswire
·
June 16, 2025
Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Flagship Communities Real Estate Investment Trust (the “REIT”) (TSX:MHC.U; MHC.UN) announced today a cash distribution of US$0. …
ORIGENCE ENHANCES ARC OS PLATFORM UNDERWRITING WITH EXPERIAN'S POWERCURVE DECISIONING INTEGRATION
GlobeNewswire
·
June 16, 2025
Irvine, California, June 16, 2025 (GLOBE NEWSWIRE) -- Origence, a leader in credit union lending technology, announced the integration of Experian’s PowerCurve® decisioning suite into the Origence arc OS loan and account origination platform. This …
Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway
GlobeNewswire
·
June 16, 2025
- New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis MONTEVIDEO, Uruguay, June 16, 2025 (GLOBE NEWSWIRE) -- Eolo Pharma, a clinical-stage biotechnology company developing …
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
June 16, 2025
WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
GlobeNewswire
·
June 16, 2025
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, …
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
GlobeNewswire
·
June 16, 2025
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit …
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
GlobeNewswire
·
June 16, 2025
Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with …
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
GlobeNewswire
·
June 16, 2025
- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19 …
Mavenir Signs Debt Recapitalization Transaction to Drive Continued Growth
GlobeNewswire
·
June 16, 2025
Transaction to strengthen Mavenir’s balance sheet and support its strategic focus on its profitable Mobile Core segment Mavenir to refocus Open RAN investments on 4G and 5G software, will accelerate investment in AI Siris to be controlling shareholder with …